Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.
針對肥胖的胰高血糖素樣受體-1激動劑:體重減輕結果、耐受性、副作用及風險。
Obes Pillars 2024-09-17
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
GLP-1受體激動劑在減重和安全性方面的差異:來自調節期的非隨機多中心研究。
Prim Care Diabetes 2023-08-01
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
GLP-1激動劑在肥胖症中的新興角色:隨機對照試驗的全面回顧。
Int J Mol Sci 2023-07-18
Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review.
糖尿病患者體重減輕的系統性回顧:葡萄糖樣肽-1受體激動劑的作用。
Cureus 2023-07-18
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
肥胖且無糖尿病個體中胰高血糖素樣肽-1受體激動劑對體重和心臟代謝參數的功效和安全性:系統性回顧和荟萃分析。
Endocr Pract 2024-02-06
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.
肥胖患者 GLP-1RAs 的功效和安全性:基於 RCT 和貝葉斯網絡荟萃分析的系統性回顧。
Biomed Pharmacother 2024-02-15
The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.
腦下垂體性肥胖患者體重控制中 GLP-1 受體激動劑的作用-系統性回顧。
Clin Obes 2024-05-13
Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?
使用結合葡萄糖樣肽1受體的藥物治療肥胖:目前情況如何?
Expert Opin Pharmacother 2024-03-27
Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients.
非糖尿病患者使用胰高血糖素樣肽-1 (GLP-1) 受體激動劑進行減重管理的療效。
Cureus 2024-08-21
The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis.
GLP-1 受體激動劑在無糖尿病的超重/肥胖青少年中的抗肥胖效果及安全性:系統性回顧與統合分析。
Cureus 2024-09-06